Astrana Health, Inc. (NASDAQ:ASTH) Receives $61.20 Average Price Target from Brokerages

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been assigned an average rating of “Buy” from the six research firms that are covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $61.20.

A number of equities analysts have recently commented on the company. Truist Financial lifted their target price on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Stifel Nicolaus lifted their target price on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. BTIG Research lifted their target price on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. Finally, Robert W. Baird lifted their target price on Astrana Health from $54.00 to $67.00 and gave the stock an “outperform” rating in a report on Thursday, August 15th.

Astrana Health Stock Performance

NASDAQ ASTH opened at $59.32 on Thursday. The stock has a market capitalization of $3.32 billion, a PE ratio of 44.94, a P/E/G ratio of 2.15 and a beta of 1.21. The business has a 50 day simple moving average of $51.26 and a two-hundred day simple moving average of $44.72. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.84 and a quick ratio of 1.84. Astrana Health has a 1-year low of $28.86 and a 1-year high of $61.51.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.01. The business had revenue of $486.30 million during the quarter, compared to analysts’ expectations of $440.68 million. Astrana Health had a return on equity of 10.71% and a net margin of 4.30%. The firm’s revenue for the quarter was up 39.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.28 EPS. On average, research analysts predict that Astrana Health will post 1.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

A number of institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in shares of Astrana Health during the 3rd quarter worth approximately $680,000. Handelsbanken Fonder AB bought a new stake in shares of Astrana Health during the 3rd quarter worth approximately $492,000. Granite Bay Wealth Management LLC bought a new stake in Astrana Health during the 3rd quarter valued at $290,000. Central Pacific Bank Trust Division bought a new stake in Astrana Health during the 3rd quarter valued at $160,000. Finally, GAMMA Investing LLC bought a new stake in Astrana Health during the 3rd quarter valued at $34,000. 52.77% of the stock is owned by institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.